Drugs / ferric gluconate
ferric gluconate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01414075 | Jul 2011 → Jan 2013 | anemia | Kyntra Bio | Completed | Missed primary |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT00224081 | Sep 2004 → May 2006 | chronic kidney disease, iron deficiency anemia | Watson Pharmaceuticals | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT00560976 | Dec 2005 → Dec 2014 | end stage renal failure | Soroka University Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00481624 Background | May 2007 → Nov 2009 | anemia | University of Louisville | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT04587141 Comparator | Jan 2020 → Jun 2023 | inflammatory bowel disease, iron deficiency anemia | Fondazione IRCCS Policlinico San Matteo di Pavia | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ferric Gluconate | “An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).” NCT00560976 ↗4“125 mg of ferric gluconate (an iron injection product), through an IV injection into a vein.” NCT00481624 ↗ “IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg” NCT01414075 ↗ |
| Known as | Ferrlecit | “An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).” NCT00560976 ↗2“ferric gluconate complex in sucrose injection [for example, Ferrlecit®] or equivalent” NCT01414075 ↗ “along with ferric gluconate, (Ferrlecit®), added for lack of iron.” NCT00481624 ↗ |
| Known as | Sodium ferric gluconate | “Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions” NCT00224081 ↗ |
| Known as | sodium ferric gluconate complex | “A cost effectiveness model was developed, consistent with the DRIVE studies, using decision analysis with a 12-week time horizon. The primary effectiveness measure was the mean...” PMID 19034302 ↗ Oct 2008 |
| Route | Intravenous | “125 mg IV given at 8 consecutive hemodialysis sessions” NCT00224081 ↗ |